Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01615068 · ClinicalTrials.gov registry record
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
A clinical trial, sponsored by Genentech.
- Completed
- Registry status
- 1,007
- Enrollment target
NCT01615068: Completed study, sponsored by Genentech.
NCT01615068 is a clinical trial that has completed, run by Genentech. The registered enrollment target is 1,007 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01615068 has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- 1,007 participants
- Enrollment target
Study Summary
This multi-center, prospective observational study will evaluate the treatment patterns, and the safety in patients with HER2-positive (HER2+) metastatic breast cancer (MBC). Eligible patients will have an initial metastatic breast cancer diagnosis that has not been previously treated with systemic therapy; patients may be enrolled up to 6 months after the diagnosis. Data will be collected for up to 8 years.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,007 participants |
| Start Date | 2012-06-05 |
| Est. Completion | 2017-11-16 |
What the finished NCT01615068 record still lists
NCT01615068 is an observational study that tracks outcomes without assigning an intervention. Its 1,007 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT01615068 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01615068 about?
NCT01615068 is a clinical study titled "An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)". This multi-center, prospective observational study will evaluate the treatment patterns, and the safety in patients with HER2-positive (HER2+) metastatic breast cancer (MBC). Eligible patients will have an initial metastatic breast cancer diagnosis that has not been previously treated with systemic ...
What is the current status of trial NCT01615068?
This trial is currently completed. The enrollment target is 1,007 participants. The study started on 2012-06-05. Estimated completion is 2017-11-16.
Who is sponsoring clinical trial NCT01615068?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07191782 · 1,008 participants · NA
Examining the Efficacy of the PRAISE With Coaching Program
- NCT04389632 · 1,006 participants · Phase 1
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- NCT06207864 · 1,001 participants · NA
Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI